Abstract: The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNF? activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNF? activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNF? antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNF? activity, such as psoriasis.

Abstract: Provided herein are novel anti-DLL3 chimeric antigen receptors and methods of using the same to treat proliferative disorders.

Abstract: The invention relates to polymeric Fc proteins which bind to human Fc-receptors and methods of screening said polymeric Fc proteins to alter their functional characteristics. The invention also relates to therapeutic compositions comprising the polymeric Fc proteins, and their use in the treatment of immune disorders.

Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1-GY-AFSSS (SEQ ID No. 1); CDR2-YPGDED (SEQ ID No. 2) CDR3-SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1-SASSSVSYMH (SEQ ID No. 4); CDR2-DTSKLAS (SEQ ID No. 5) CDR3-QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and suberoylanilide hydroxamic acid (SAHA), and the use of the combination therapies for the treatment of caner.

Abstract: Provided are methods of treatments with combinations or compositions containing a soluble hyaluronidase, such as a polymer-modified hyaluronidase, and an immune checkpoint inhibitor treating cancers, including solid and non-solid tumors. The combinations and compositions also are provided.

Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.

Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.

Abstract: Compositions and methods for treating solid tumors such as pancreatic ductal adenocarcinoma (PDA) via interfering with the Dectin-1 signaling pathway, for example, using Dectin-1 or Galectin-9 inhibitors.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

Abstract: The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.

Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting to domain 3 of human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of cancers, such as leukemias and melanoma.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: The present invention relates to engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions.

Abstract: The present invention features compositions and methods for enhancing an anti-tumor response by administering an OX40 agonist (e.g., an anti-OX40 antibody) and/or an anti-CTLA4 antibody (e.g., a CTLA4-blocking antibody) in combination with a cancer therapy.

Abstract: The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.

Abstract: The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Abstract: Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.

Abstract: The present invention relates to the interaction between JMJD6 protein and collagen and to the possibility of inhibiting this interaction for the prevention and treatment of fibrosis and of tumor metastases. The invention further relates to a compound that is able to block the interaction between collagen and JMJD6 protein, in particular the invention relates to a new monoclonal antibody that recognizes JMJD6 and is able to block this interaction.

Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.

Abstract: The present invention provides an antibody having an activity to specifically bind to human membrane-anchored form ADAM28 at an epitope in a region of the 524th-659th amino acids in the amino acid sequence shown in SEQ ID NO: 2. In addition, the present invention provides a drug delivery vehicle for delivering a drug to a cell or tissue that expresses human membrane-anchored form ADAM28, which contains the antibody.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating osteoporosis using such molecular constructs are also disclosed.

Abstract: Described is a method for processing cellulose-containing biomass with sulfuric acid and certain additives, especially for the pretreatment of cellulose-containing biomass prior to saccharification.

Abstract: The present invention relates to a phase-stable suspension of cellulose II in water, having a high water retention capacity and a cellulose concentration between 0.1 and 5.0% by weight, a method of its preparation, and its use.

Abstract: An object of the present invention is to provide a ?-1,3-glucan derivative which is a polymer having ?-1,3-glucan as a main chain, and has thermoplasticity and excellent moldability, and a preparation method thereof. That is, the present invention provides a ?-1,3-glucan derivative having a structure represented by General Formula (1) as a main chain. (In Formula (1), each of a plurality of R1s independently represents a hydrogen atom or —COR2, n represents an integer of 1 or greater, and R2 represents an aliphatic hydrocarbon group or an aromatic hydrocarbon group. In Formula (1), a plurality of the R1s may be the same as or different from each other, and at least a part of a plurality of the R1s is —COR2.

Abstract: A chondroitin sulfate preparation process and device thereof and in particular a process for extracting ten thousand tons of chondroitin sulfate by means of a solvent-free process is disclosed. The process comprises steps such as liquefaction, extraction, enzymolysis and degradation, filtering, separation and after-treatment. The device comprises a reaction kettle. The reaction kettle is preferably a Teflon reaction kettle. The reaction kettle is in pipeline connection with a vacuum circulation filter, a filtrate storage tank and a molecular sieve in sequence. The molecular sieve is separately in pipeline connection with a protein fluid storage tank and a CS solution storage tank. The present invention has the advantages of low investment. Compared to the same production scale, the investment is cut by 80%. The larger the production scale is the more advantageous in investment. The production capacity is over million tons, which is unattainable by solvent-process technology.

Abstract: This present disclosure relates to a method of producing a proteoglycan having anticoagulant activity, comprising of and providing a cell transfected with a recombinant nucleic acid encoding a core protein having one or more glycosaminoglycan attachment sites; and incubating the cell under conditions to promote the production of a proteoglycan comprising the core protein linked to heparin and/or HS and optionally other glycosaminoglycan chains, and to heparin or heparan sulphate isolated from such proteoglycans that have significant anti-coagulant activity.

Abstract: The invention relates to graft copolymers (B) composed of an agglomerated graft core (B1) and at least one graft shell (B2) and also to copolymers (C) having an agglomerating effect, a method for producing said graft copolymers (B), thermoplastic molding compositions and also the use of the thermoplastic molding compositions.

Abstract: Disclosed are optical compensation films with exceptionally high positive out-of-plane birefringence. The optical compensation films are based on substituted styrenic fluoropolymers and have positive out-of-plane bireftingence greater than 0.02 throughout the wavelength range of 400 nm<?<800 nm. The optical compensation films of the invention are suitable for use in optical devices such as liquid crystal display (LCD) devices and organic light emitting diode (OLED) display devices.

Abstract: Disclosed herein is a method comprising the steps of: a) producing a hydrocarbon stream from syngas via a Fischer-Tropsch reaction, wherein the hydrocarbon stream comprises a first C2 hydrocarbon stream comprising ethane and a first ethylene product; b) separating at least a portion of the first C2 hydrocarbon stream from the hydrocarbon stream; c) separating at least a portion of the first ethylene product from the first C2 hydrocarbon stream, thereby producing a second C2 hydrocarbon stream; d) converting at least a portion of the ethane in the second C2 hydrocarbon stream to a second ethylene product; and e) producing polyethylene from at least a portion of the second ethylene product.

Abstract: Disclosed herein are dual catalyst compositions containing an unbridged metallocene compound, a bridged metallocene compound, a chemically-treated solid oxide, and an optional co-catalyst. These catalyst compositions can be used for the oligomerization of propylene to produce an oligomer product. For example, a heavy propylene oligomer can be recovered from the oligomer product, and the heavy propylene oligomer can be characterized by a high flash point and viscosity index, and a low pour point.

Abstract: Disclosed is a process for making nitrated styrenic fluoropolymers having various degrees of substitution. The nitrated styrenic fluoropolymer is capable of providing an exceptionally high birefringence ranging from 0.02 to 0.036. Further, the birefringence can be tuned by varying the degree of substitution (DS) of the nitro group on the styrenic ring to meet the need for optical compensation film applications. More particularly, the optical compensation films of the present invention are for use in an in-plane switching LCD (IPS-LCD) and OLED display.

Abstract: Novel stress-reducing crosslinking oligomers that have application in dental restoratives, thin films, hardcoats, composites, adhesives, and other uses subject to stress reduction are described. The addition-fragmentation process of crosslinking results in a chain-transfer event that provides novel polymers that may be further functionalized. In addition, the addition-fragmentation oligomer comprises pendent functional groups that bond to a substrate by forming an ionic or covalent bond, or etch the substrate by chemically removing some material from the substrate.

Abstract: Embodiments encompassing a series of compositions containing polymers of norbornadiene and maleic anhydride monomers which are useful in forming a variety of photopatternable structures are disclosed and claimed. The compositions are useful as permanent dielectric materials. More specifically, embodiments encompassing compositions containing a series of ter- and tetrapolymers of a variety of norbornadiene, maleic anhydride, maleimide and norbornene-type cycloolefinic monomers in which maleic anhydride is fully or partially hydrolyzed (i.e., ring opened and fully or partially esterified), and a photoactive compound are disclosed, which are useful in forming permanent dielectric materials having utility in a variety of electronic material applications, among various other uses.

Abstract: The invention relates to a metallocene complex according to formula (1) wherein M is a metal selected from lanthanides or transition metals from group 3, 4, 5 or 6 of the Periodic System of the Elements, Q is an anionic ligand to M, k is the number of Q groups and equals the valence of M minus 2, Z1, Z2, Z3 and Z4 are identical or different and can be chosen from the group consisting of hydrogen and a hydrocarbon radical with 1-20 carbon atoms, and adjacent substituents Z can form a ring system together with the carbon atoms of the Cp ring to which they are bound.

Abstract: Dispersing agents useful in a suspension polymerization process may be formed based on polyvinyl alcohols and processes discloses herein. The dispersing agent may include, for example: a polyvinyl alcohol having a degree of hydrolysis in the range from 60 to 80 mol %; an absorbance of not less than 0.3 measured at a wavelength of 320 nm with respect to a 0.1 wt % aqueous solution of the polyvinyl alcohol; a block character of remaining ester groups in the range from 0.4 to 0.5; and a cloud point in the range from 35° C. to 50° C. measured with respect to a 1 wt % aqueous solution of the polyvinyl alcohol. Carbonyl groups are theorized to be present along the polymer chain, which may be quantified by 1-H NMR spectra peaks.

Abstract: The present invention provides a catalyst composition including a functionalizing agent of the following Formula 1 together with a rare earth metal compound, an alkylating agent, and a halogen compound, having good catalytic activity and polymerization reactivity and useful for the preparation of a conjugated diene-based polymer having high linearity and excellent processability, and a conjugated diene-based polymer prepared using the catalyst composition. (X1)a—Si—(X2)4-a,??[Formula 1] In Formula 1, a, X1, and X2 are the same as defined in the disclosure.

Abstract: Disclosed is a solution polymerization process, or, alternatively, a method of delivering powder catalysts to a solution polymerization reactor, comprising combining a homogeneous single-site catalyst precursor with ?-olefin monomers to form a polyolefin, wherein the homogeneous single-site catalyst precursor is in the form of (i) a dry powder, (ii) suspended in a aliphatic hydrocarbon solvent, or (iii) suspended in an oil or wax, wherein the homogeneous single-site catalyst precursor is at a concentration greater than 0.8 mmole/liter when suspended in the aliphatic hydrocarbon solvent prior to entering the solution polymerization reactor.

Abstract: A crosslinked metallocene-catalyzed polyethylene copolymer having a higher molecular weight (HMW) component and lower molecular weight (LMW) component wherein the HMW component is present in an amount of from about 10 wt. % to about 30 wt. % and wherein the LMW component is present in an amount of from about 70 wt. % to about 90 wt. %.

Abstract: An iso-styrene:diene-terminated copolymer is described which includes (i) a polymeric block of styrene and/or substituted styrene consisting of a sequence of styrene and/or substituted styrene in isotactic configuration, and (ii) a terminal polymeric block consisting of a sequence of one or more dienic monomers.

Abstract: The invention relates to a heterogeneous, co-continuous copolymer composition of vinylidene fluoride and at least one other comonomer. Preferred comonomers are hexafluoropropylene and perfluoroalkylvinyl ether. The co-continuous morphology is provide by first forming a first phase polymer, then adding one or more comonomers before half of the original monomer stream has been added, and at an effective level to cause phase separation of the copolymer. The co-continuous morphology provides a means for incorporating a high level of comonomer into the copolymer with little or no adverse effect on the melting temperature. The morphology also provides the copolymer composition with a unique combination of properties, including a high melting point, good flexibility and good low temperature impact resistance. The unique properties of the polymer make it useful in end-use application where those properties provide performance advantages, such as in the wire and cable market, and in oil and gas applications.

Abstract: A method for making an ophthalmic lens includes following steps of providing a mixture comprising a hydrophilic monomer, a clay, a cross-linking agent, an initiator, and a solvent; and feeding the mixture into a mold and exposing the mixture to ultraviolet radiation or heating the mixture, to cause the hydrophilic monomer, the cross-linking agent, and the initiator in the mixture to undergo a polymerization reaction to form a cross-linking network, and the clay in the mixture to be dispersed in the cross-linking network, thereby forming the ophthalmic lens. The disclosure also provides an ophthalmic lens made by above method, and an ophthalmic lens material making for the ophthalmic lens.

Abstract: The present invention relates to the field of shape memory materials. Specifically, a shape memory polymer, a preparation method therefor, and use thereof are provided. The shape memory polymer is formed by polymerizing methyl ally polyethenoxy ether and 2-(dimethylamino)ethyl methacrylate. The synthesis steps of the shape memory polymer are simplified, the preparation method is simple, and the production cost is low. In addition, the shape memory polymer prepared in the present invention has excellent shape memory performance and high hydrophilicity and biocompatibility, and is suitable for preparing biomedical materials in the field of biomedical science.

Abstract: Non-ionic photo-acid generating (PAG) polymerizable monomers were prepared that contain a side chain sulfonate ester of an alpha-hydroxy aryl ketone. The aryl ketone group has a perfluorinated substituent alpha to the ketone carbonyl. The sulfur of the sulfonate ester is also directly linked to a fluorinated group. PAG polymers prepared from the PAG monomers release a strong sulfonic acid when exposed to high energy radiation such as deep UV or extreme UV light. The photo-generated sulfonic acid has a low diffusion rate in an exposed resist layer subjected to a post-exposure bake (PEB) at 100° C. to 150° C., resulting in formation of good line patterns after development.

Abstract: The present disclosure relates to an acrylic processing aid and a vinyl chloride resin composition including the same, and in particular, to a core-shell-structured acrylic processing aid preparing a core using a silicone-azo macroinitiator and preparing a shell using C12 to C18 alkyl methacrylate as a co-monomer, and a vinyl chloride resin composition including the same. The acrylic processing aid is used for sheet forming of the vinyl chloride resin, and facilitates manufacture of a high-quality vinyl chloride resin formed article having excellent transparency, adhesion resistance and heat stability, having no non-dispersed melt (fish-eye) production, and having significantly reduced air mark and flow mark occurrences.

Abstract: The invention relates to a reaction product UA of at least one cyclic urea U and at least one multifunctional aldehyde A which reaction product has as substituents on the carbonyl carbon atoms of the aldehyde A at least one kind of functional groups selected from the group consisting of hydroxyl groups —OH and alkoxy groups —OR characterised in that the groups —OR comprise at least two kinds of alkoxy groups —OR1 and —OR2, where R1 and R2 are both selected from the group consisting of linear, branched or cyclic alkyl groups having from one to twelve carbon atoms, where R1 and R2 may be the same or may be different from each other, to a process of making these, and to a method of use as crosslinker in coating compositions.

Abstract: The present invention relates to a binder system which contains an isocyanate-terminated polyurethane prepolymer as the resin component and a polyol mixture as the curing agent, said polyol mixture containing at least one alkoxylated diamine. The invention also relates to the use of the binder system as an adhesive/sealing material, in particular as a laminating adhesive for food packaging.

Abstract: The use of a mixture (M) comprising nitrogen compound(s) in the preparation of polyurethanes, especially polyurethane foams, wherein said mixture (M) comprises the following constituents: (a) N,N-dimethylaminopropylamine, at least in an amount of ?5% by weight, advantageously in an amount of ?20% by weight, preferably 20%-95% by weight, further preferably 30%-70% by weight, especially 30%-60% by weight, and (b) at least one solvent, especially water, advantageously in a total amount of ?5% by weight, preferably ?10% by weight, more preferably 10%-60% by weight, especially 10%-40% by weight, % by weight based in each case on the overall mixture (M), is described.